- Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU -
- 82% of CSU patients reported that symptoms no longer had an impact on their quality of life at Week 52 -
- 60% of CIndU patients reported that symptoms no longer had an impact on their quality of life at Week 12 -
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
Seeking Alpha / 21 hours ago 5 Views
Comments